Phase I dose escalation study of the PI3kinase pathway inhibitor BKM120 and the oral poly (ADP ribose) polymerase (PARP) inhibitor olaparib for the treatment of high-grade serous ovarian and breast cancer

U. A. Matulonis, G. M. Wulf, W. T. Barry, M. Birrer, S. N. Westin, S. Farooq, K. M. Bell-McGuinn, E. Obermayer, C. Whalen, T. Spagnoletti, W. Luo, H. Liu, R. C. Hok, C. Aghajanian, D. B. Solit, Gordon Mills, B. S. Taylor, H. Won, M. F. Berger, S. PalakurthiJ. Liu, L. C. Cantley, E. Winer

Research output: Contribution to journalArticle

61 Scopus citations


Background: Based upon preclinical synergy in murine models, we carried out a phase I trial to determine the maximum tolerated dose (MTD), toxicities, pharmacokinetics, and biomarkers of response for the combination of BKM120, a PI3K inhibitor, and olaparib, a PARP inhibitor. Patients and methods: Olaparib was administered twice daily (tablet formulation) and BKM120 daily on a 28-day cycle, both orally. A 3+3 dose-escalation design was employed with the primary objective of defining the combination MTD, and secondary objectives were to define toxicities, activity, and pharmacokinetic profiles. Eligibility included recurrent breast (BC) or ovarian cancer (OC); dose-expansion cohorts at the MTD were enrolled for each cancer. Results: In total, 69 of 70 patients enrolled received study treatment; one patient never received study treatment because of ineligibility. Twenty-four patients had BC; 46 patients had OC. Thirty-five patients had a germline BRCA mutation (gBRCAm). Two DLTs (grade 3 transaminitis and hyperglycemia) were observed at DL0 (BKM120 60 mg/olaparib and 100mg b.i.d.). The MTD was determined to be BKM120 50mg q.d. and olaparib 300mg b.i.d. (DL8). Additional DLTs included grade 3 depression and transaminitis, occurring early in cycle 2 (DL7). Anticancer activity was observed in BC and OC and in gBRCAmand gBRCA wild-type (gBRCAwt) patients. Conclusions: BKM120 and olaparib can be co-administered, but the combination requires attenuation of the BKM120 dose. Clinical benefit was observed in both gBRCAm and gBRCAwt pts. Randomized phase II studies will be needed to further define the efficacy of PI3K/PARP-inhibitor combinations as compared with a PARP inhibitor alone.

Original languageEnglish (US)
Pages (from-to)512-518
Number of pages7
JournalAnnals of Oncology
Issue number3
Publication statusPublished - Jan 1 2017
Externally publishedYes



  • BKM120
  • Breast cancer
  • Olaparib
  • Ovarian cancer
  • PARP-inhibitors

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this